Agent | Targeting site | Phase | No. of evaluable patients | Type of patients | Outcomes | ClinicalTrial.gov ID | References |
---|---|---|---|---|---|---|---|
Tipifarnib | Farnesyltransferase inhibitor | II | 12 | PTCL | 50Â % ORR | NCT00082888 | [49] |
Darinaparsin | Organic arsenic compound | II | 7 | PTCL | 28.6Â % ORR, 3.6Â months median TTF, 6.4Â months OS | NCT00421213 | [50] |
Panobinostat | Pan-deacetylase inhibitor | II | 139 | CTCL | 17.3Â % ORR | NCT00425555 | [51] |
Denileukin diftitox | Interleukin fusion protein | III | 263 | CTCL | 38Â % ORR, median DoR was 277Â days | NCT00050999 | [52] |
NCT00051012 | |||||||
Ixazomib | Proteasome inhibitor | I | 4 | PTCL | 1 PR | NCT00893464 | [53] |
Sorafenib | Multikinase inhibitor | — | 12 | PTCL/CTCL | 42 % ORR, 4 CR, 1 PR | — | [54] |
Forodesine | PNP inhibitor | II | 101 | CTCL | No CR, 11Â % PR, 50Â % SD, median DoR was 191Â days | NCT00501735 | [55] |